Acusphere has announced the completion of enrollment in the second of its two Phase III clinical trials, RAMP-2 (Real-time Assessment of Myocardial Perfusion-2), for the company's lead product candidate AI-700. Separately, the company announced results for the RAMP-1 clinical trial and an intellectual property license with GE Healthcare. AI-700 is an investigational ultrasound contrast agent designed to assess myocardial perfusion, or blood flow to the heart muscle.
The company has closed the RAMP-2 clinical trial and, as required by the trial design, is now in the 30-day post-enrollment follow-up period for the most recent patients enrolled in this clinical trial. Once this follow-up period is completed and all patient angiography data are collected, an independent third-party clinical research organization, on behalf of the company, will conduct quality control checks.